Marker Therapeutics, Inc. (MRKR) P/E Ratio History
Historical price-to-earnings valuation from 2016 to 2016
Loading P/E history...
MRKR Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Marker Therapeutics, Inc. (MRKR) trades at a price-to-earnings ratio of -1.8x, with a stock price of $1.44 and trailing twelve-month earnings per share of $-794488.57.
The current P/E is 119% below its 5-year average of 9.4x. Over the past five years, MRKR's P/E has ranged from a low of 9.4x to a high of 9.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, MRKR trades at a 108% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, MRKR trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MRKR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MRKR P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 15.5Lowest | -Best | +1747%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
MRKR Historical P/E Data (2016–2016)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2016 Q2 | $61.20 | $6.52 | 9.4x | +0% |
Average P/E for displayed period: 9.4x
See MRKR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRKR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRKR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMRKR — Frequently Asked Questions
Quick answers to the most common questions about buying MRKR stock.
Is MRKR stock overvalued or undervalued?
MRKR trades at -1.8x P/E, below its 5-year average of 9.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does MRKR's valuation compare to peers?
Marker Therapeutics, Inc. P/E of -1.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is MRKR's PEG ratio?
MRKR PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2016-2016.